Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Says that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignancies in China. The first patient received their first dose on May 31. ‘This is a Phase I, multicenter, open-label clinical study to evaluate the safety, pharmacokinetics and efficacy of HMPL-506 in patients with hematological malignancies. The study is divided into two phases, a dose escalation phase and a dose expansion phase. The study is expected to enroll at least 60 patients,’ Hutchmed says. HMPL-506 is a novel, investigational, selective small molecule inhibitor for oral administration targeting the menin protein, it explains.
Current stock price: 280.00 pence each, down 3.5% in London on Friday
12-month change: up 43%
Copyright 2024 Alliance News Ltd. All Rights Reserved.
